SynAct Pharma AB (SYNACT) AI Stock Analysis

• Market Cap: €1.22B
• Dividend Yield: N/A
• Average Volume (3M): 214.83K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.23
• Revenue Growth: N/A
• EPS Growth: 48.14%
• Country: SE
• Employees: 6
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.68
• Shares Outstanding: 53,330,242
• 10 Day Avg. Volume: 154,831
• 30 Day Avg. Volume: 214,829
• PEG Ratio: 0.06
• Price to Book (P/B): 1.66
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -3.98
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 48 Neutral
• Price Target: ―

SynAct Pharma AB's stock score reflects the company's early-stage development in the biotech industry, characterized by no revenue and ongoing financial losses, but supported by a strong equity position. Technical indicators show positive momentum, albeit with signs of being overbought. The valuation is uncertain due to negative earnings, highlighting both the potential and risks inherent in investing in pre-revenue biotech firms.

SynAct Pharma AB Business Overview & Revenue Model

Company Description

SynAct Pharma AB, through its subsidiary, SynAct Pharma ApS, develops medicines for acute deterioration in inflammatory diseases. The company is developing AP1189, a drug candidate for the treatment of rheumatoid arthritis and idiopathic membranous glomerulonephritis. It has a partnership with the University Of Örebro to study the reduction of inflammation in vascular disease. The company was founded in 2012 and is headquartered in Lund, Sweden.

How the Company Makes Money

SynAct Pharma makes money primarily through the development and eventual commercialization of its pharmaceutical products. Revenue streams are expected to include licensing agreements, partnerships with larger pharmaceutical companies, and sales of its developed drugs upon regulatory approval. The company may also receive milestone payments and royalties from its partnerships. As typical in the biotech sector, SynAct Pharma may also rely on funding from investors and grants to support ongoing research and development activities until its products reach the market.

SynAct Pharma AB Financial Statement Overview

Summary

SynAct Pharma AB is in a pre-revenue stage, typical for biotech firms focused on R&D. The company maintains a strong equity position with minimal debt, which is positive. However, ongoing losses and reliance on external funding underscore financial risks, highlighting the need for future revenue generation to ensure long-term sustainability.

Income Statement

SynAct Pharma AB has consistently reported zero revenue over the years, indicating the company's pre-revenue stage typical of many biotech firms focused on R&D. The net income remains deeply negative, highlighting substantial losses due to ongoing operational expenses, with no revenue offset. The absence of gross profit and continuous negative EBIT and EBITDA margins reflect the company's current focus on development rather than profitability.

Balance Sheet

The company's balance sheet shows a strong equity position with low debt levels, evidenced by a low Debt-to-Equity ratio. However, the Return on Equity is negative due to persistent losses. The Equity Ratio is healthy, indicating reliance on shareholder equity rather than debt for funding. These factors suggest financial stability but also highlight the need for eventual revenue generation.

Cash Flow

SynAct Pharma AB's cash flow statements reveal consistent negative operating and free cash flows, typical for a biotech company investing heavily in R&D. There is no free cash flow growth due to ongoing losses. The company's financing cash flow is positive, indicating reliance on external funding to maintain operations, which poses a risk if fundraising becomes challenging in the future.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	0.00	-617.00K	-778.00K	-1.06M	-88.00K	0.00
EBITDA	-103.55M	-15.40M	-222.70M	-105.71M	-76.62M	-30.90M
Net Income	-91.07M	-82.40M	-215.81M	-99.20M	-69.30M	-26.55M
Balance Sheet
Total Assets	243.59M	270.52M	228.02M	142.60M	38.37M	21.59M
Cash, Cash Equivalents and Short-Term Investments	68.89M	61.21M	62.40M	108.25M	24.00M	14.55M
Total Debt	1.54M	1.88M	637.00K	2.06M	3.09M	0.00
Total Liabilities	47.18M	56.35M	51.83M	16.08M	17.50M	5.72M
Stockholders Equity	196.41M	214.17M	176.19M	126.52M	20.87M	15.87M
Cash Flow
Free Cash Flow	-41.90M	-89.20M	-100.18M	-117.56M	-65.00M	-33.24M
Operating Cash Flow	-41.90M	-89.20M	-100.18M	-117.56M	-65.00M	-33.24M
Investing Cash Flow	0.00	0.00	370.00K	27.00K	-6.00K	-93.00K
Financing Cash Flow	40.13M	87.41M	53.98M	200.71M	74.32M	44.72M

SynAct Pharma AB Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 21.30
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:SYNACT, the sentiment is Positive. The current price of 21.3 is below the 20-day moving average (MA) of 21.75, below the 50-day MA of 21.93, and above the 200-day MA of 19.27, indicating a neutral trend. The MACD of -0.27 indicates Positive momentum. The RSI at 47.97 is Neutral, neither overbought nor oversold. The STOCH value of 49.51 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:SYNACT.

SynAct Pharma AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SANION	76 Outperform	€2.18B	8.11	114.45%	―	2687.51%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ONCO	50 Neutral	kr1.38B	―	―	―	131.20%	32.28%
SYNACT	48 Neutral	€1.22B	-10.49	-58.41%	―	―	48.14%
ACE	43 Neutral	€390.59M	-2.68	-79.60%	―	―	31.62%
GUARD	32 Underperform	€28.23M	-0.16	-199.25%	―	―	0.30%
CANTA	31 Underperform	€815.45M	-4.15	81.19%	―	―	―